Hint mode is switched on Switch off

Alaunos Therapeutics, ordinary share
TCRT, US98973P1012

Add a stock to WL
Choose all Reset all
Alaunos Therapeutics, сountry — USA
01/02/2024 stock stopped trading due to affiliation to Alaunos Therapeutics, ordinary share
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Issuer

Profile
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related ...
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Alaunos Therapeutics Inc (formerly ZIOPHARM Oncology, Inc.)
  • Industry
    Pharmaceutical Preparation and Biotechnology

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide

Indicators

News

09/04/2026 Alaunos Therapeutics: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing
02/03/2026 Alaunos Therapeutics: Other Events, – Financial Statements And Exhibits
08/01/2026 Alaunos Therapeutics: Termination Of A Material Definitive Agreement, Material Modification To Rights Of Security Holders, Other Events, – Financial Statements And Exhibits
17/12/2025 Alaunos Therapeutics: Entry Into A Material Definitive Agreement, – Financial Statements And Exhibits
19/08/2025 Alaunos Therapeutics: Other Events
All organization news

Other stocks and deposit receipts

Holders

Industry Leaders

Registration is required to get access.